In Vivo Characterization of a Novel 𝜸-Secretase Inhibitor SCH 697466 in Rodents and Investigation of Strategies for Managing Notch-Related Side Effects

Figure 4

(a) Aβ40 levels expressed as a percent of vehicle in plasma and cortex, (b) thymus weight, and (c) percent area in the ileum covered by PAS stain following 6 days of b.i.d. administration of SCH 697466 to TgCRND8 mice. The final dose of SCH 697466 was given on day six 3 hr prior to tissue harvesting. ^∗𝑃<0.0006 versus vehicle, Dunnett post hoc test.

(a)

(b)

(c)